A randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin

Abstract Background Type 2 diabetes mellitus (T2DM) is a major public health concern with growing prevalence with multiple debilitating complications. GlycaCare-II is a proprietary herbal formulation supplement for T2DM containing extracts of Cinnamomum cassia, Momordica charantia, Pterocarpus marsu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Muhammed Majeed, Anju Majeed, Kalyanam Nagabhusahnam, Lakshmi Mundkur, Shaji Paulose
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	GlycaCare-II Metformin Glycosylated hemoglobin Fasting blood sugar and postprandial blood sugar Prediabetic Newly diagnosed diabetic and type 2 diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/b210bd29830c478fa5deb5e7d7ec8568
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b210bd29830c478fa5deb5e7d7ec8568
record_format	dspace
spelling	oai:doaj.org-article:b210bd29830c478fa5deb5e7d7ec85682021-11-21T12:40:15ZA randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin10.1186/s13098-021-00746-01758-5996https://doaj.org/article/b210bd29830c478fa5deb5e7d7ec85682021-11-01T00:00:00Zhttps://doi.org/10.1186/s13098-021-00746-0https://doaj.org/toc/1758-5996Abstract Background Type 2 diabetes mellitus (T2DM) is a major public health concern with growing prevalence with multiple debilitating complications. GlycaCare-II is a proprietary herbal formulation supplement for T2DM containing extracts of Cinnamomum cassia, Momordica charantia, Pterocarpus marsupium, Gymnema sylvestre, Salacia reticulata, Eugenia jambolana, and a bioavailability enhancer piperine from Piper nigrum. Objective The antihyperglycemic potential of GlycaCare-II was compared against metformin in a double-blind study. Design It was a randomized, two-arm design on prediabetic (N = 29; 12 in metformin and 17 in GlycaCare-II arm, respectively) and newly diagnosed diabetic (N = 40; 16 in metformin and 24 in GlycaCare-II) patients for 120 days. Outcome measures Changes in diabetic panel glycosylated hemoglobin (HbA1c), fasting blood sugar (FBS), and postprandial blood sugar (PBS) were the primary endpoints. Lipid profile, liver profile, thyroid-stimulating hormone, bilirubin and creatinine were the secondary endpoints. Result Twice a day treatment for 120 days with GlycaCare-II led to a statistically significant change in HbA1c (p < 0.001), FBS (p < 0.001), PBS (p < 0.001) on both prediabetic and newly diagnosed diabetic patients. GlycaCare-II showed a similar potential as metformin in the treatment of T2DM. In the prediabetic group, both GlycaCare-II and metformin were comparable for all the hyperglycemic index parameters. In the case of newly diagnosed diabetic patients, GlycaCare-II showed a significantly better reduction for PBS (p = 0.026) as compared to metformin, while all other parameters in the diabetic panel were comparable. No adverse events were reported throughout the trial period. Conclusion These results suggest that GlycaCare-II is effective in managing T2DM in both newly diagnosed diabetic and prediabetic patients.Muhammed MajeedAnju MajeedKalyanam NagabhusahnamLakshmi MundkurShaji PauloseBMCarticleGlycaCare-IIMetforminGlycosylated hemoglobinFasting blood sugar and postprandial blood sugarPrediabeticNewly diagnosed diabetic and type 2 diabetes mellitusNutritional diseases. Deficiency diseasesRC620-627ENDiabetology & Metabolic Syndrome, Vol 13, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	GlycaCare-II Metformin Glycosylated hemoglobin Fasting blood sugar and postprandial blood sugar Prediabetic Newly diagnosed diabetic and type 2 diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	GlycaCare-II Metformin Glycosylated hemoglobin Fasting blood sugar and postprandial blood sugar Prediabetic Newly diagnosed diabetic and type 2 diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627 Muhammed Majeed Anju Majeed Kalyanam Nagabhusahnam Lakshmi Mundkur Shaji Paulose A randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin
description	Abstract Background Type 2 diabetes mellitus (T2DM) is a major public health concern with growing prevalence with multiple debilitating complications. GlycaCare-II is a proprietary herbal formulation supplement for T2DM containing extracts of Cinnamomum cassia, Momordica charantia, Pterocarpus marsupium, Gymnema sylvestre, Salacia reticulata, Eugenia jambolana, and a bioavailability enhancer piperine from Piper nigrum. Objective The antihyperglycemic potential of GlycaCare-II was compared against metformin in a double-blind study. Design It was a randomized, two-arm design on prediabetic (N = 29; 12 in metformin and 17 in GlycaCare-II arm, respectively) and newly diagnosed diabetic (N = 40; 16 in metformin and 24 in GlycaCare-II) patients for 120 days. Outcome measures Changes in diabetic panel glycosylated hemoglobin (HbA1c), fasting blood sugar (FBS), and postprandial blood sugar (PBS) were the primary endpoints. Lipid profile, liver profile, thyroid-stimulating hormone, bilirubin and creatinine were the secondary endpoints. Result Twice a day treatment for 120 days with GlycaCare-II led to a statistically significant change in HbA1c (p < 0.001), FBS (p < 0.001), PBS (p < 0.001) on both prediabetic and newly diagnosed diabetic patients. GlycaCare-II showed a similar potential as metformin in the treatment of T2DM. In the prediabetic group, both GlycaCare-II and metformin were comparable for all the hyperglycemic index parameters. In the case of newly diagnosed diabetic patients, GlycaCare-II showed a significantly better reduction for PBS (p = 0.026) as compared to metformin, while all other parameters in the diabetic panel were comparable. No adverse events were reported throughout the trial period. Conclusion These results suggest that GlycaCare-II is effective in managing T2DM in both newly diagnosed diabetic and prediabetic patients.
format	article
author	Muhammed Majeed Anju Majeed Kalyanam Nagabhusahnam Lakshmi Mundkur Shaji Paulose
author_facet	Muhammed Majeed Anju Majeed Kalyanam Nagabhusahnam Lakshmi Mundkur Shaji Paulose
author_sort	Muhammed Majeed
title	A randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin
title_short	A randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin
title_full	A randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin
title_fullStr	A randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin
title_full_unstemmed	A randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin
title_sort	randomized, double-blind clinical trial of a herbal formulation (glycacare-ii) for the management of type 2 diabetes in comparison with metformin
publisher	BMC
publishDate	2021
url	https://doaj.org/article/b210bd29830c478fa5deb5e7d7ec8568
work_keys_str_mv	AT muhammedmajeed arandomizeddoubleblindclinicaltrialofaherbalformulationglycacareiiforthemanagementoftype2diabetesincomparisonwithmetformin AT anjumajeed arandomizeddoubleblindclinicaltrialofaherbalformulationglycacareiiforthemanagementoftype2diabetesincomparisonwithmetformin AT kalyanamnagabhusahnam arandomizeddoubleblindclinicaltrialofaherbalformulationglycacareiiforthemanagementoftype2diabetesincomparisonwithmetformin AT lakshmimundkur arandomizeddoubleblindclinicaltrialofaherbalformulationglycacareiiforthemanagementoftype2diabetesincomparisonwithmetformin AT shajipaulose arandomizeddoubleblindclinicaltrialofaherbalformulationglycacareiiforthemanagementoftype2diabetesincomparisonwithmetformin AT muhammedmajeed randomizeddoubleblindclinicaltrialofaherbalformulationglycacareiiforthemanagementoftype2diabetesincomparisonwithmetformin AT anjumajeed randomizeddoubleblindclinicaltrialofaherbalformulationglycacareiiforthemanagementoftype2diabetesincomparisonwithmetformin AT kalyanamnagabhusahnam randomizeddoubleblindclinicaltrialofaherbalformulationglycacareiiforthemanagementoftype2diabetesincomparisonwithmetformin AT lakshmimundkur randomizeddoubleblindclinicaltrialofaherbalformulationglycacareiiforthemanagementoftype2diabetesincomparisonwithmetformin AT shajipaulose randomizeddoubleblindclinicaltrialofaherbalformulationglycacareiiforthemanagementoftype2diabetesincomparisonwithmetformin
_version_	1718418908956852224

A randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin

Ejemplares similares